Funding for bladder cancer (BC) research has fallen behind that provided for other malignancies. This is especially the case for junior individuals. Therefore our SPORE In BC has provided one of the unique resources for seed funding available to promising young laboratory and clinical scientists with a special interest in pursuing independent translational research in BC. The overall goal of the Career Development Program (CDP) is to support and mentor when appropriate the scientific careers of these individuals to expand the number of such talented young investigators. Funding for bladder cancer focused research has lagged behind support provided for other malignancies.
The specific aims of the CDP within this Bladder Cancer SPORE renewal builds on the strengths of our current SPORE which included. Recruiting innovative entry-level and junior scientists into The University of Texas MD Anderson Cancer Center Bladder Cancer SPORE to enhance its overall translational BC research capability. Providing the opportunity for individuals with previous experience in the research and treatment of cancer at other disease sites who wish to develop expertise in BC. Promote the careers of the selected scientists by facilitating the development of skills necessary to be productive independent investigators in BC translational research. Train clinical oncologists and basic scientists who can rapidly translate basic observations in cellular and molecular biology into clinically applicable BC research programs and the design of protocols.

Public Health Relevance

BC ranks 4th in terms of incidence and 1st in terms of clinical management cost among human malignancies. The training of young investigators with an interest in both basic and translational BC research are vital to provide future scientists who can impact the overall out come of this disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA091846-12
Application #
8745007
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (O1))
Project Start
2001-09-25
Project End
2017-08-31
Budget Start
2013-09-12
Budget End
2014-08-31
Support Year
12
Fiscal Year
2013
Total Cost
$159,545
Indirect Cost
$67,884
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Duplisea, Jonathan J; Mokkapati, Sharada; Plote, Devin et al. (2018) The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol :
Choi, Woonyoung; McConkey, David (2018) Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas D Eur Urol 73:e104-e105
Zhang, Miao; Adeniran, Adebowale J; Vikram, Raghunandan et al. (2018) Carcinoma of the urethra. Hum Pathol 72:35-44
Wang, Gang; Xiao, Li; Zhang, Miao et al. (2018) Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol 79:57-65
Zhang, Shizhen; Wang, Yan; Bondaruk, Jolanta et al. (2018) Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. Eur Urol Focus :
Jazzar, Usama; Yong, Shan; Klaassen, Zachary et al. (2018) Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States. Cancer 124:3127-3135
Westhoff, Ellen; Wu, Xifeng; Kiemeney, Lambertus A et al. (2018) Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. Int J Cancer 142:1797-1804
Roth, Beat; Jayaratna, Isuru; Sundi, Debasish et al. (2017) Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. Oncotarget 8:34205-34222
Shore, Neal D; Boorjian, Stephen A; Canter, Daniel J et al. (2017) Intravesical rAd-IFN?/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol 35:3410-3416
Lin, Moubin; Zhang, Liren; Hildebrandt, Michelle A T et al. (2017) Common, germline genetic variations in the novel tumor suppressor BAP1 and risk of developing different types of cancer. Oncotarget 8:74936-74946

Showing the most recent 10 out of 247 publications